These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

407 related articles for article (PubMed ID: 32964651)

  • 21. HIV-Associated Dementia: Associated Factors and Characteristics of Cognitive Domain Abnormalities in Elderly People Living with HIV Treated with Highly Active Antiretroviral Therapy.
    Boonyagars L; Kiatsoongsong N; Winitprichagul S
    Am J Trop Med Hyg; 2022 Dec; 107(6):1250-1257. PubMed ID: 36315995
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Neurological soft signs as a marker of cognitive impairment severity in people living with HIV.
    Toro P; Ceballos ME; Pesenti J; Inostroza M; Valenzuela D; Henríquez F; Forno G; Herold C; Schröder J; Calderón J
    Psychiatry Res; 2018 Aug; 266():138-142. PubMed ID: 29870954
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Screening for HIV-Associated Neurocognitive Disorder (HAND) in Adults Aged 50 and Over Attending a Government HIV Clinic in Kilimanjaro, Tanzania. Comparison of the International HIV Dementia Scale (IHDS) and IDEA Six Item Dementia Screen.
    Kellett-Wright J; Flatt A; Eaton P; Urasa S; Howlett W; Dekker M; Kisoli A; Duijinmaijer A; Thornton J; McCartney J; Yarwood V; Irwin C; Mukaetova-Ladinska E; Akinyemi R; Lwezuala B; Gray WK; Walker RW; Dotchin CL; Makupa P; Paddick SM
    AIDS Behav; 2021 Feb; 25(2):542-553. PubMed ID: 32875460
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Low levels of neurocognitive impairment detected in screening HIV-infected men who have sex with men: The MSM Neurocog Study.
    Barber TJ; Bansi L; Pozniak A; Asboe D; Nelson M; Moyle G; Davies N; Margetts A; Ratcliffe D; Catalan J; Boffito M; Gazzard B
    Int J STD AIDS; 2017 Jun; 28(7):715-722. PubMed ID: 27510645
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Development of a neurocognitive test battery for HIV-associated neurocognitive disorder (HAND) screening: suggested solutions for resource-limited clinical settings.
    Chan LG; Ho MJ; Lin YC; Ong Y; Wong CS
    AIDS Res Ther; 2019 Apr; 16(1):9. PubMed ID: 30987670
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Use of Western Neuropsychological Test Battery in Detecting HIV-Associated Neurocognitive Disorders (HAND) in Zambia.
    Kabuba N; Anitha Menon J; Franklin DR; Heaton RK; Hestad KA
    AIDS Behav; 2017 Jun; 21(6):1717-1727. PubMed ID: 27278547
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Addenbrooke's cognitive examination-revised: normative and accuracy data for seniors with heterogeneous educational level in Brazil.
    César KG; Yassuda MS; Porto FHG; Brucki SMD; Nitrini R
    Int Psychogeriatr; 2017 Aug; 29(8):1345-1353. PubMed ID: 28511735
    [TBL] [Abstract][Full Text] [Related]  

  • 28. HIV-associated neurocognitive disorders at Moi teaching and referral hospital, Eldoret, Kenya.
    Mohamed AA; Oduor C; Kinyanjui D
    BMC Neurol; 2020 Jul; 20(1):280. PubMed ID: 32664858
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Screening for neurocognitive impairment in HIV-positive adults aged 50 years and older: Montreal Cognitive Assessment relates to self-reported and clinician-rated everyday functioning.
    Fazeli PL; Casaletto KB; Paolillo E; Moore RC; Moore DJ; The Hnrp Group
    J Clin Exp Neuropsychol; 2017 Nov; 39(9):842-853. PubMed ID: 28122474
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Addenbrooke's Cognitive Examination-Third Edition Predicts Neuropsychological Test Performance.
    Zarrella GV; Kay CD; Gettens K; Sherman JC; Colvin MK
    J Neuropsychiatry Clin Neurosci; 2023; 35(2):178-183. PubMed ID: 35989574
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Neuropsychological tests associated with symptomatic HIV-associated neurocognitive disorder (HAND) in a cohort of older adults in Tanzania.
    Fotheringham L; Lawson RA; Urasa S; Boshe J; Mukaetova-Ladinska EB; Rogathi J; Howlett W; Dekker MCJ; Gray WK; Evans J; Walker RW; Makupa PC; Paddick SM
    J Int Neuropsychol Soc; 2024 Aug; 30(7):660-670. PubMed ID: 38766814
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Psychometric properties and diagnostic usefulness of the Addenbrooke's Cognitive Examination-Revised in a Chilean elderly sample].
    Muñoz-Neira C; Henríquez Ch F; Ihnen J J; Sánchez C M; Flores M P; Slachevsky Ch A
    Rev Med Chil; 2012 Aug; 140(8):1006-13. PubMed ID: 23282773
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Validation of the Cuban Version of Addenbrooke's Cognitive Examination-Revised for Screening Mild Cognitive Impairment.
    Broche-Pérez Y; López-Pujol HA
    Dement Geriatr Cogn Disord; 2017; 44(5-6):320-327. PubMed ID: 29393151
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Psychometric utility of the international HIV dementia scale and Montreal Cognitive Assessment in HIV-associated asymptomatic neurocognitive impairment.
    Aita SL; Kaewpoowat Q; Yasri S; Rerkasem A; Rerkasem K; Choovuthayakorn J; Ausayakhun S; Robertson K; Roth RM; Robbins NM
    J Neurovirol; 2021 Aug; 27(4):568-578. PubMed ID: 34185242
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The validity of the Addenbrooke's Cognitive Examination-Revised (ACE-R) in acute stroke.
    Morris K; Hacker V; Lincoln NB
    Disabil Rehabil; 2012; 34(3):189-95. PubMed ID: 21954948
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Improving Detection of HIV-Associated Cognitive Impairment: Comparison of the International HIV Dementia Scale and a Brief Screening Battery.
    de Almeida SM; Kamat R; Cherner M; Umlauf A; Ribeiro CE; de Pereira AP; Franklin D; Heaton RK; Ellis RJ
    J Acquir Immune Defic Syndr; 2017 Mar; 74(3):332-338. PubMed ID: 27828876
    [TBL] [Abstract][Full Text] [Related]  

  • 37. HIV-Associated Neurocognitive Disorders: The First Longitudinal Follow-Up of a cART-Treated Cohort of Older People in Sub-Saharan Africa.
    Spooner R; Ranasinghe S; Urasa S; Yoseph M; Koipapi S; Mukaetova-Ladinska EB; Lewis T; Howlett W; Dekker M; Kisoli A; Gray WK; Walker RW; Dotchin CL; Kalaria R; Lwezuala B; Makupa PC; Akinyemi R; Paddick SM
    J Acquir Immune Defic Syndr; 2022 Jun; 90(2):214-222. PubMed ID: 35125473
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Validation of the German revised Addenbrooke's cognitive examination for detecting mild cognitive impairment, mild dementia in alzheimer's disease and frontotemporal lobar degeneration.
    Alexopoulos P; Ebert A; Richter-Schmidinger T; Schöll E; Natale B; Aguilar CA; Gourzis P; Weih M; Perneczky R; Diehl-Schmid J; Kneib T; Förstl H; Kurz A; Danek A; Kornhuber J
    Dement Geriatr Cogn Disord; 2010; 29(5):448-56. PubMed ID: 20502019
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparing Sensitivity and Specificity of Addenbrooke's Cognitive Examination-I, III and Mini-Addenbrooke's Cognitive Examination in Parkinson's Disease.
    Lucza T; Ascherman Z; Kovács M; Makkos A; Harmat M; Juhász A; Janszky J; Komoly S; Kovács N; Dorn K; Karádi K
    Behav Neurol; 2018; 2018():5932028. PubMed ID: 30369997
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sensitivity of the Mini-Mental State Examination, Montreal Cognitive Assessment and the Addenbrooke's Cognitive Examination III to everyday activity impairments in dementia: an exploratory study.
    Giebel CM; Challis D
    Int J Geriatr Psychiatry; 2017 Oct; 32(10):1085-1093. PubMed ID: 27593974
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.